• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

工程细胞因子在癌症和自身免疫性疾病免疫治疗中的应用。

Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy.

机构信息

Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30322, USA.

Department of Pediatrics, Emory School of Medicine, Atlanta, GA, 30322, USA.

出版信息

Adv Healthc Mater. 2021 Aug;10(15):e2002214. doi: 10.1002/adhm.202002214. Epub 2021 Mar 9.

DOI:10.1002/adhm.202002214
PMID:33690997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8651077/
Abstract

Cytokine signaling is critical to a range of biological processes including cell development, tissue repair, aging, and immunity. In addition to acting as key signal mediators of the immune system, cytokines can also serve as potent immunotherapies with more than 20 recombinant products currently Food and Drug Administration (FDA)-approved to treat conditions including hepatitis, multiple sclerosis, arthritis, and various cancers. Yet despite their biological importance and clinical utility, cytokine immunotherapies suffer from intrinsic challenges that limit their therapeutic potential including poor circulation, systemic toxicity, and low tissue- or cell-specificity. In the past decade in particular, methods have been devised to engineer cytokines in order to overcome such challenges and here, the myriad strategies are reviewed that may be employed in order to improve the therapeutic potential of cytokine and chemokine immunotherapies with applications in cancer and autoimmune disease therapy, as well as tissue engineering and regenerative medicine. For clarity, these strategies are collected and presented as they vary across size scales, ranging from single amino acid substitutions, to larger protein-polymer conjugates, nano/micrometer-scale particles, and macroscale implants. Together, this work aims to provide readers with a timely view of the field of cytokine engineering with an emphasis on early-stage therapeutic approaches.

摘要

细胞因子信号转导对于一系列生物学过程至关重要,包括细胞发育、组织修复、衰老和免疫。除了作为免疫系统的关键信号介质外,细胞因子还可以作为有效的免疫疗法,目前已有 20 多种重组产品获得美国食品和药物管理局(FDA)批准,用于治疗包括肝炎、多发性硬化症、关节炎和各种癌症在内的多种疾病。然而,尽管细胞因子免疫疗法具有重要的生物学意义和临床应用价值,但它们仍存在内在的挑战,限制了其治疗潜力,包括循环不良、全身毒性和低组织或细胞特异性。特别是在过去十年中,人们设计了多种方法来工程化细胞因子,以克服这些挑战。在这里,我们综述了可以用于提高细胞因子和趋化因子免疫疗法治疗癌症和自身免疫性疾病以及组织工程和再生医学的治疗潜力的各种策略。为了清晰起见,这些策略是按照大小尺度进行收集和呈现的,从单个氨基酸取代到更大的蛋白-聚合物缀合物、纳米/微米级颗粒和宏观植入物。总之,这项工作旨在为读者提供细胞因子工程领域的最新观点,重点介绍早期治疗方法。

相似文献

1
Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy.工程细胞因子在癌症和自身免疫性疾病免疫治疗中的应用。
Adv Healthc Mater. 2021 Aug;10(15):e2002214. doi: 10.1002/adhm.202002214. Epub 2021 Mar 9.
2
Self-Assembly as a Molecular Strategy to Improve Immunotherapy.自组装作为一种提高免疫疗法的分子策略。
Acc Chem Res. 2020 Nov 17;53(11):2534-2545. doi: 10.1021/acs.accounts.0c00438. Epub 2020 Oct 19.
3
Advances in immunotherapy delivery from implantable and injectable biomaterials.免疫疗法在可植入和可注射生物材料中的应用进展。
Acta Biomater. 2019 Apr 1;88:15-31. doi: 10.1016/j.actbio.2019.02.016. Epub 2019 Feb 13.
4
Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases. Toll 样受体诱导的细胞因子作为癌症和自身免疫性疾病的免疫治疗靶点。
Semin Cancer Biol. 2020 Aug;64:61-82. doi: 10.1016/j.semcancer.2019.05.002. Epub 2019 May 2.
5
Mechanical Immunoengineering of T cells for Therapeutic Applications.T 细胞的机械免疫工程用于治疗应用。
Acc Chem Res. 2020 Dec 15;53(12):2777-2790. doi: 10.1021/acs.accounts.0c00486. Epub 2020 Dec 1.
6
Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases.cGAS-STING 免疫调节剂的工程设计与递送及其在癌症和自身免疫性疾病免疫治疗中的应用。
Acc Chem Res. 2023 Nov 7;56(21):2933-2943. doi: 10.1021/acs.accounts.3c00394. Epub 2023 Oct 6.
7
Concise review: engineering the fusion of cytokines for the modulation of immune cellular responses in cancer and autoimmune disorders.简要综述:构建细胞因子融合体以调节癌症和自身免疫性疾病中的免疫细胞反应
Stem Cells Transl Med. 2015 Jan;4(1):66-73. doi: 10.5966/sctm.2014-0145. Epub 2014 Nov 12.
8
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发:现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
9
Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.工程化的 IL-21 细胞因子突变体与抗 PD-1 抗体融合可改善 CD8+T 细胞功能和抗肿瘤免疫。
Front Immunol. 2020 May 8;11:832. doi: 10.3389/fimmu.2020.00832. eCollection 2020.
10
Cytokine engineering for targeted cancer immunotherapy.细胞因子工程靶向癌症免疫治疗。
Curr Opin Chem Biol. 2021 Jun;62:43-52. doi: 10.1016/j.cbpa.2021.01.007. Epub 2021 Mar 6.

引用本文的文献

1
Innovative Formulation Strategies for Biosimilars: Trends Focused on Buffer-Free Systems, Safety, Regulatory Alignment, and Intellectual Property Challenges.生物类似药的创新制剂策略:聚焦无缓冲系统、安全性、监管一致性及知识产权挑战的趋势
Pharmaceuticals (Basel). 2025 Jun 17;18(6):908. doi: 10.3390/ph18060908.
2
Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation.白血病治疗中的纳米技术:革新靶向药物递送与免疫调节
Clin Exp Med. 2025 May 17;25(1):166. doi: 10.1007/s10238-025-01686-z.
3
Optimized lipid nanoparticles enable effective CRISPR/Cas9-mediated gene editing in dendritic cells for enhanced immunotherapy.

本文引用的文献

1
Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective.聚乙二醇化干扰素治疗药物临床性能改善的分子见解:分子动力学视角
RSC Adv. 2018 Jan 9;8(5):2315-2322. doi: 10.1039/c7ra12480e.
2
Void-free 3D Bioprinting for In-situ Endothelialization and Microfluidic Perfusion.用于原位内皮化和微流控灌注的无孔隙3D生物打印
Adv Funct Mater. 2019 Nov 11;30(1). doi: 10.1002/adfm.201908349. eCollection 2020 Jan 3.
3
Rapid Assembly and Screening of Multivalent Immune Cell-Redirecting Therapies for Leukemia.
优化的脂质纳米颗粒可在树突状细胞中实现有效的CRISPR/Cas9介导的基因编辑,以增强免疫疗法。
Acta Pharm Sin B. 2025 Jan;15(1):642-656. doi: 10.1016/j.apsb.2024.08.030. Epub 2024 Oct 11.
4
The Genetic Causal Effect of Autoimmune Diseases on pan-Cancers: Evidence from Mendelian Randomization.自身免疫性疾病对泛癌的遗传因果效应:来自孟德尔随机化的证据。
J Cancer. 2025 Jan 1;16(2):567-576. doi: 10.7150/jca.103693. eCollection 2025.
5
DNA Damage-driven Inflammatory Cytokines: Reprogramming of Tumor Immune Microenvironment and Application of Oncotherapy.DNA 损伤驱动的炎症细胞因子:肿瘤免疫微环境的重编程及其在肿瘤治疗中的应用。
Curr Med Sci. 2024 Apr;44(2):261-272. doi: 10.1007/s11596-024-2859-1. Epub 2024 Apr 2.
6
Framework Nucleic Acids-Based VEGF Signaling Activating System for Angiogenesis: A Dual Stimulation Strategy.基于框架核酸的血管内皮生长因子信号激活系统用于血管生成:一种双重刺激策略。
Adv Sci (Weinh). 2024 Jun;11(21):e2308701. doi: 10.1002/advs.202308701. Epub 2024 Mar 9.
7
Bioorthogonal dissociative rhenium(i) photosensitisers for controlled immunogenic cell death induction.用于可控诱导免疫原性细胞死亡的生物正交解离铼(I)光敏剂
Chem Sci. 2023 Oct 24;14(46):13508-13517. doi: 10.1039/d3sc04903e. eCollection 2023 Nov 29.
8
The application of Interleukin-2 family cytokines in tumor immunotherapy research.白细胞介素-2 家族细胞因子在肿瘤免疫治疗研究中的应用。
Front Immunol. 2023 Mar 2;14:1090311. doi: 10.3389/fimmu.2023.1090311. eCollection 2023.
9
Multicolor Light-Induced Immune Activation via Polymer Photocaged Cytokines.多色光诱导的聚合物光封闭细胞因子免疫激活。
Biomacromolecules. 2023 Mar 13;24(3):1164-1172. doi: 10.1021/acs.biomac.2c01207. Epub 2023 Feb 6.
10
Evolution of γ chain cytokines: Mechanisms, methods and applications.γ链细胞因子的演变:机制、方法与应用。
Comput Struct Biotechnol J. 2022 Aug 25;20:4746-4755. doi: 10.1016/j.csbj.2022.08.050. eCollection 2022.
快速组装和筛选用于白血病的多价免疫细胞重定向疗法。
ACS Comb Sci. 2020 Oct 12;22(10):533-541. doi: 10.1021/acscombsci.0c00081. Epub 2020 Aug 18.
4
Cancer Cell Coating Nanoparticles for Optimal Tumor-Specific Cytokine Delivery.用于优化肿瘤特异性细胞因子递送的癌细胞包被纳米颗粒
ACS Nano. 2020 Sep 22;14(9):11238-11253. doi: 10.1021/acsnano.0c03109. Epub 2020 Sep 5.
5
Defining the Threshold IL-2 Signal Required for Induction of Selective Treg Cell Responses Using Engineered IL-2 Muteins.定义诱导选择性 Treg 细胞反应所需的 IL-2 信号阈值:使用工程化的 IL-2 突变体。
Front Immunol. 2020 Jun 5;11:1106. doi: 10.3389/fimmu.2020.01106. eCollection 2020.
6
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.立体定向消融体部放疗 (SABR) 联合免疫疗法 (L19-IL2) 与 IV 期 NSCLC 患者标准治疗比较:ImmunoSABR 多中心、随机对照开放标签 II 期试验。
BMC Cancer. 2020 Jun 15;20(1):557. doi: 10.1186/s12885-020-07055-1.
7
Cellular backpacks for macrophage immunotherapy.细胞背包用于巨噬细胞免疫治疗。
Sci Adv. 2020 Apr 29;6(18):eaaz6579. doi: 10.1126/sciadv.aaz6579. eCollection 2020 May.
8
Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.工程化的 IL-21 细胞因子突变体与抗 PD-1 抗体融合可改善 CD8+T 细胞功能和抗肿瘤免疫。
Front Immunol. 2020 May 8;11:832. doi: 10.3389/fimmu.2020.00832. eCollection 2020.
9
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).贝姆培加德白介素(NKTR - 214)联合纳武利尤单抗治疗晚期实体瘤患者:安全性、疗效及免疫激活的I期剂量递增研究(PIVOT - 02)
Cancer Discov. 2020 Aug;10(8):1158-1173. doi: 10.1158/2159-8290.CD-19-1510. Epub 2020 May 21.
10
Optical Control of Cytokine Signaling via Bioinspired, Polymer-Induced Latency.通过仿生、聚合物诱导潜伏期对细胞因子信号进行光学控制。
Biomacromolecules. 2020 Jul 13;21(7):2635-2644. doi: 10.1021/acs.biomac.0c00264. Epub 2020 May 29.